A COST-EFFECTIVENESS ANA LYSIS OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES AND COLORECTAL CANCER

被引：2
|
作者：
Soon, S. [1 ]
Chia, W. J. [2 ]
Redekop, K. [3 ]
Wee, H. L. [1 ]
机构：
[1] Natl Univ Singapore, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Singapore, Singapore
[3] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1200
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN183
引用
收藏
页码：A462 / A462
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
    Lee, Mei-Chuan
    Liao, Chia-Te
    Toh, Han Siong
    Chou, Chih-Chen
    Chang, Wei-Ting
    Chen, Zhih-Cherng
    Wu, Wen-Shiann
    Yu, Tsung
    Strong, Carol
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (03) : 539 - 547
  • [32] COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS FOR PREVENTION OF GASTROINTESTINAL ADVERSE EVENTS WHEN USING ASPIRIN FOR PRIMARY CARDIOVASCULAR PREVENTION
    Earnshaw, S.
    Pignone, M.
    Fendrick, A. M.
    Scheiman, J. M.
    McDade, C.
    VALUE IN HEALTH, 2010, 13 (03) : A166 - A166
  • [33] Cost-effectiveness comparison of breast cancer screening and vascular event primary prevention with aspirin in Wales
    Morgan, Gareth
    HEALTH EDUCATION JOURNAL, 2011, 70 (03) : 296 - 300
  • [34] Pravastatin cost-effectiveness for primary prevention of cardiovascular disease in the US
    Hay, JW
    Yuan, Y
    Ford, I
    McGuire, A
    Shepherd, J
    CIRCULATION, 1997, 96 (08) : 1017 - 1017
  • [35] Prevention of Colorectal Cancer by Aspirin and/or Calcium: Efficacy, Mechanisms, and Cost Effectiveness
    Pence, Barbara C.
    Belasco, Eric J.
    Lyford, Conrad P.
    CURRENT COLORECTAL CANCER REPORTS, 2012, 8 (01) : 51 - 56
  • [36] Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
    Jiang, Minghuan
    Li, Pengchao
    You, Joyce Hoi-sze
    Zheng, Xinglong
    Deng, Jizhao
    Zhao, Mingyue
    Feng, Liuxin
    Fang, Yu
    PLOS ONE, 2019, 14 (12):
  • [37] A cost-effectiveness analysis of low-dose Aspirin in the primary prevention of cardiovascular disease in four European countries
    Lamotte, M
    Annemans, L
    Evers, T
    Kubin, M
    VALUE IN HEALTH, 2005, 8 (06) : A98 - A99
  • [38] Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk
    Greving, Jacoba P.
    Buskens, Erik
    Koffijberg, Hendrik
    Algra, Ale
    CIRCULATION, 2008, 117 (22) : 2875 - 2883
  • [39] COST-EFFECTIVENESS ANA LYSIS OF REGORAFENIB FOR THIRD-LINE METASTATIC COLORECTAL CANCER (MCRC) COMPARED TO CETUXIMAB PLUS IRINOTECAN IN CHINA
    Liu, J.
    Zhu, S.
    Sun, W.
    Tao, L.
    Xiao, D.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S33 - S33
  • [40] Aspirin in primary prevention of cardiovascular and cerebrovascular diseases
    Gassanov, Natig
    Eicke, Martin
    Er, Fikret
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (20) : 1353 - 1359
12345